

The Baxter logo is centered in the upper half of the page. It features the word "Baxter" in a bold, italicized, blue sans-serif font. The background consists of a white diamond shape in the center, surrounded by four quadrants of overlapping diagonal stripes in shades of blue, gold, and light grey.

Partnering Search for Nutrition

2019



Our Mission

SAVE AND
SUSTAIN LIVES

Baxter Profile: Global Patient Impact



60M+ patients
treated annually



Products in **100+**
countries




47,000 employees
worldwide

Global Revenue



\$11.1B
2018 Sales

Revenue by Region



Advancing Healthcare: Our Six Global Business Units



RENAL CARE

Pioneering therapy options for people with kidney disease, including peritoneal dialysis and hemodialysis



ADVANCED SURGERY

Enabling surgeons to act with precision and speed to minimize complications and increase efficiency



PHARMACEUTICALS

Providing generic injectable medicines and inhaled anesthetics that are critical to effective patient care across the globe



MEDICATION DELIVERY

Advanced infusion systems and solutions to help ensure the right treatment is delivered safely and efficiently



NUTRITION

Leading clinical nutrition solutions formulated to help patients maintain or regain their health



ACUTE THERAPIES

Innovative products and therapies that treat life-threatening conditions in the ICU

Project Call

Enteral Feeding Intolerance 2019

Calling all innovators:

Prediction & Detection of Enteral Feeding Intolerance (EFI)

Background

- Enteral Nutrition (EN) is the preferred method of nutrition support when patients cannot be fed orally.
- However, about **40% of adult ICU patients will develop EN feeding intolerance** leading to negative outcomes ⁽¹⁾
- Current standard for measuring EN intolerance is poor indicator; yet novel technologies are still early-stage ^(2, 3)

Baxter's Call Objective

- We seek partners that have products/technologies (finished or under development) that **directly assess parameters associated with EN intolerance** at an early stage.
- The selected approaches must provide information for **better clinical decision making** to start/stop/alter enteral feeding.

Stage: From Proof of Concept through to Marketed solutions

Format: Please submit a non-confidential summary:

Either 2 pages or 10 slides max

Deadline: 30th October 2019

Submit by sending your summary to:
nathalie_cospin@baxter.com (Nutrition)
simon_turner@baxter.com (EU scouting)

1. Journal of ICM; 2017, Vol. 32(9) 540-546, 2.JPEN J Parenter Enteral Nutr. 2015;39:441-448; 3.JAMA. 2013;309(3):249-256;